ArticleFrontiers in oncology2021
Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Research progress of MRI-based radiomics in hepatocellular carcinoma.Frontiers in oncology · 2025Pooled it
- Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.La Radiologia medica · 2024Pooled it
- Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis.Abdominal radiology (New York) · 2026Review
- Interpretable radiomics model based on magnetic resonance imaging to predict responses to transarterial chemoembolization for hepatocellular carcinoma.World journal of radiology · 2026Article
- AI models based on gadoxetic acid-enhanced MRI to predict treatment response and prognosis after TACE in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Artificial intelligence in imaging diagnosis of liver tumors: current status and future prospects.Abdominal radiology (New York) · 2026Review
- Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Article
- Development and Validation of a Radiomics Nomogram Based on Magnetic Resonance Imaging and Clinicoradiological Factors to Predict HCC TACE Refractoriness.Cancer management and research · 2025Article
- A Dual-Sequence MRI-Based Radiomics Model for Predicting High-Intensity Focused Ultrasound Ablation Efficacy in Adenomyosis Treatment.International journal of women's health · 2025Article
- TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Assessment of Y-90 Radioembolization Treatment Response for Hepatocellular Carcinoma Cases Using MRI Radiomics.Molecular imaging and radionuclide therapy · 2024Article
- Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Current status of magnetic resonance imaging radiomics in hepatocellular carcinoma: A quantitative review with Radiomics Quality Score.World journal of gastroenterology · 2024Review
- A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.La Radiologia medica · 2024Article
- Multisequence MRI-Based Radiomic Features Combined with Inflammatory Indices for Predicting the Overall Survival of HCC Patients After TACE.Journal of hepatocellular carcinoma · 2024Article
- Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model.Frontiers in pharmacology · 2024Article
- MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.BMC medical imaging · 2023Article
- Hepatocellular carcinoma: State of the art diagnostic imaging.World journal of radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of contrast-enhanced magnetic resonance imaging (CE-MRI) radiomics for pretherapeutic prediction of the response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
methodsOne hundred and twenty-two HCC patients (objective response,
resultsAmong all radiomics models, the three-phase radiomics model exhibited better performance in the training cohort with an area under the curve (AUC) of 0.838 (95% confidence interval (CI), 0.753 - 0.922), which was verified in the validation cohort (AUC, 0.833; 95% CI, 0.691 - 0.975). The combined model that integrated the three-phase radiomics score and clinical-radiological risk factors (total bilirubin, tumor shape, and tumor encapsulation) showed excellent calibration and predictive capability in the training and validation cohorts with AUCs of 0.878 (95% CI, 0.806 - 0.950) and 0.833 (95% CI, 0.687 - 0.979), respectively, and showed better predictive ability (
conclusionCE-MRI radiomics analysis may serve as a promising and noninvasive tool to predict therapeutic response to TACE in HCC, which will facilitate the individualized follow-up and further therapeutic strategies guidance in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.